Piscine-derived pyy peptides for use in treating a metabolic disorder
AssigneeUniversity of Ulster
InventorsNigel Irwin, Peter Raymond Flatt
Life of this patent
Estimating the term…
Abstract
The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder; wherein the peptide is a piscine-derived PYY or fragment or analogue thereof.
Claims17
A piscine-derived PYY peptide for use in the treatment of a metabolic disorder.
The peptide for use according to any preceding claim;
- wherein the peptide comprises an amino acid sequence having at least 60% identity to a sequence selected from the group comprising:
- SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, and SEQ ID NO:
- 7.
The peptide for use according to any preceding claim;
- wherein the peptide comprises the amino acid sequence defined by a sequence selected from the group comprising:
- SEQ ID NO:
- 9, SEQ ID NO:
- 10, and SEQ ID NO:
- 11.
The peptide for use according to any preceding claim;
- wherein the use of the peptide in the treatment of a metabolic disorder has no significant impact on patient appetite.
The peptide for use according to any preceding claim;
- wherein the use of the peptide in the treatment of a metabolic disorder has no significant impact on patient appetite, compared to a comparable dose of human PYY(1-36).
The peptide for use according to any preceding claim;
- wherein the peptide has a half life of greater than 2 hours under physiological conditions.
The peptide for use according to any preceding claim;
- wherein the peptide has a half life of greater than 2 hours against cleavage and/or degradation by DPP-4 or C-terminally directed protease enzymes.
The peptide for use according to any preceding claim;
- wherein the use comprises administration of the peptide during a pre-determined first period during every 24 hours.
The peptide for use according to any preceding claim;
- wherein the use comprises administration of the peptide within a pre-determined period of time before or while the patient is asleep.
The peptide for use according to any preceding claim;
- wherein the use comprises administration of the peptide in alternating combination with at least one GLP-1 receptor agonist.
The peptide for use according to any preceding claim;
- wherein the metabolic disorder is a pancreatic disorder.
The peptide for use according to any preceding claim;
- wherein the metabolic disorder comprises diabetes mellitus.
Dependencies are inferred from the claim text.